Showing results (171-180 of 230) with videos related to
Sort By:
Pageof 23
Journal of the National Comprehensive Cancer Network : JNCCN|May 10, 2012
Cancer- and chemotherapy-induced anemiaGeorge M Rodgers, Pamela Sue Becker, Morey Blinder, et al.European Journal of Cancer (Oxford, England : 1990)|July 22, 2021
Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapyAngelina Tjokrowidjaja, Michael Friedlander, Sarah J Lord, et al.The Lancet. Oncology|September 15, 2014
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 studyJoyce F Liu, William T Barry, Michael Birrer, et al.Experimental Dermatology|April 28, 2005
Two mouse mutations mapped to chromosome 11 with differing morphologies but similar progressive inflammatory alopeciaGeoffrey A Wood, Ann Flenniken, Lucy Osborne, et al.Cancers|June 2, 2021
Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M Checkpoint Deficient TP53 Mutant Uterine Carcinomas Is Linked to the Summation of LKB1-AKT-p53 InteractionsKatherine N Lynch, Joyce F Liu, Nikolas Kesten, et al.Nature Communications|May 31, 2022
STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancerQiwei Wang, Johann S Bergholz, Liya Ding, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 29, 2022
A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial CancerPanagiotis A Konstantinopoulos, Elizabeth K Lee, Niya Xiong, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2019
The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP InhibitionKalindi Parmar, Bose S Kochupurakkal, Jean-Bernard Lazaro, et al.Nature Communications|March 27, 2026
Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trialRebecca L Porter, Yinglu Zhou, Nebiyat Eskndir, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2019
Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA TrialUrsula A Matulonis, Lydia Walder, Trine J Nøttrup, et al.Pageof 23